213 related articles for article (PubMed ID: 30098338)
1. Temporal and Spatial Epigenome Editing Allows Precise Gene Regulation in Mammalian Cells.
Kuscu C; Mammadov R; Czikora A; Unlu H; Tufan T; Fischer NL; Arslan S; Bekiranov S; Kanemaki M; Adli M
J Mol Biol; 2019 Jan; 431(1):111-121. PubMed ID: 30098338
[TBL] [Abstract][Full Text] [Related]
2. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements.
Thakore PI; D'Ippolito AM; Song L; Safi A; Shivakumar NK; Kabadi AM; Reddy TE; Crawford GE; Gersbach CA
Nat Methods; 2015 Dec; 12(12):1143-9. PubMed ID: 26501517
[TBL] [Abstract][Full Text] [Related]
3. Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells.
Okada M; Kanamori M; Someya K; Nakatsukasa H; Yoshimura A
Epigenetics Chromatin; 2017; 10():24. PubMed ID: 28503202
[TBL] [Abstract][Full Text] [Related]
4. Epigenome editing of the CFTR-locus for treatment of cystic fibrosis.
Kabadi AM; Machlin L; Dalal N; Lee RE; McDowell I; Shah NN; Drowley L; Randell SH; Reddy TE
J Cyst Fibros; 2022 Jan; 21(1):164-171. PubMed ID: 34049825
[TBL] [Abstract][Full Text] [Related]
5. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.
Hilton IB; D'Ippolito AM; Vockley CM; Thakore PI; Crawford GE; Reddy TE; Gersbach CA
Nat Biotechnol; 2015 May; 33(5):510-7. PubMed ID: 25849900
[TBL] [Abstract][Full Text] [Related]
6. Keeping our eyes on CRISPR: the "Atlas" of gene editing.
Wang W; Hou J; Zheng N; Wang X; Zhang J
Cell Biol Toxicol; 2019 Aug; 35(4):285-288. PubMed ID: 31165372
[No Abstract] [Full Text] [Related]
7. CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome.
Klann TS; Black JB; Chellappan M; Safi A; Song L; Hilton IB; Crawford GE; Reddy TE; Gersbach CA
Nat Biotechnol; 2017 Jun; 35(6):561-568. PubMed ID: 28369033
[TBL] [Abstract][Full Text] [Related]
8. CRISPR as a strong gene editing tool.
Shen S; Loh TJ; Shen H; Zheng X; Shen H
BMB Rep; 2017 Jan; 50(1):20-24. PubMed ID: 27616359
[TBL] [Abstract][Full Text] [Related]
9. Interrogation of enhancer function by enhancer-targeting CRISPR epigenetic editing.
Li K; Liu Y; Cao H; Zhang Y; Gu Z; Liu X; Yu A; Kaphle P; Dickerson KE; Ni M; Xu J
Nat Commun; 2020 Jan; 11(1):485. PubMed ID: 31980609
[TBL] [Abstract][Full Text] [Related]
10. Battling CRISPR-Cas9 off-target genome editing.
Li D; Zhou H; Zeng X
Cell Biol Toxicol; 2019 Oct; 35(5):403-406. PubMed ID: 31313008
[No Abstract] [Full Text] [Related]
11. Minimizing off-target effects in CRISPR-Cas9 genome editing.
Chen SJ
Cell Biol Toxicol; 2019 Oct; 35(5):399-401. PubMed ID: 31317359
[No Abstract] [Full Text] [Related]
12. Gene editing and gene regulation with CRISPR.
Harrison P; Hart S
Exp Physiol; 2018 Apr; 103(4):437-438. PubMed ID: 29603460
[No Abstract] [Full Text] [Related]
13. Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems.
O'Connell MR
J Mol Biol; 2019 Jan; 431(1):66-87. PubMed ID: 29940185
[TBL] [Abstract][Full Text] [Related]
14. A CRISPR-dCas Toolbox for Genetic Engineering and Synthetic Biology.
Xu X; Qi LS
J Mol Biol; 2019 Jan; 431(1):34-47. PubMed ID: 29958882
[TBL] [Abstract][Full Text] [Related]
15. Establishment of Cell Lines Stably Expressing dCas9-Fusions to Address Kinetics of Epigenetic Editing.
Goubert D; Koncz M; Kiss A; Rots MG
Methods Mol Biol; 2018; 1767():395-415. PubMed ID: 29524148
[TBL] [Abstract][Full Text] [Related]
16. Generation and validation of versatile inducible CRISPRi embryonic stem cell and mouse model.
Li R; Xia X; Wang X; Sun X; Dai Z; Huo D; Zheng H; Xiong H; He A; Wu X
PLoS Biol; 2020 Nov; 18(11):e3000749. PubMed ID: 33253175
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Directed Gene Editing Catalyzes Precise Gene Segment Replacement
Sansbury BM; Wagner AM; Tarcic G; Barth S; Nitzan E; Goldfus R; Vidne M; Kmiec EB
CRISPR J; 2019 Apr; 2():121-132. PubMed ID: 30998096
[TBL] [Abstract][Full Text] [Related]
18. Harnessing CRISPR-Cas9 for Epigenetic Engineering.
Guerra-Resendez RS; Hilton IB
Methods Mol Biol; 2022; 2518():237-251. PubMed ID: 35666449
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-Cas12 and Cas13: the lesser known siblings of CRISPR-Cas9.
Yan F; Wang W; Zhang J
Cell Biol Toxicol; 2019 Dec; 35(6):489-492. PubMed ID: 31468291
[No Abstract] [Full Text] [Related]
20. Engineered miniature CRISPR-Cas system for mammalian genome regulation and editing.
Xu X; Chemparathy A; Zeng L; Kempton HR; Shang S; Nakamura M; Qi LS
Mol Cell; 2021 Oct; 81(20):4333-4345.e4. PubMed ID: 34480847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
